Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Other Accumulated Expenses (2019 - 2026)

Biodesix filings provide 8 years of Other Accumulated Expenses readings, the most recent being $927000.0 for Q1 2026.

  • On a quarterly basis, Other Accumulated Expenses fell 57.69% to $927000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $927000.0, a 57.69% decrease, with the full-year FY2025 number at $992000.0, down 58.23% from a year prior.
  • Other Accumulated Expenses hit $927000.0 in Q1 2026 for Biodesix, down from $992000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $3.5 million in Q1 2024 to a low of $37000.0 in Q1 2022.
  • Median Other Accumulated Expenses over the past 5 years was $2.1 million (2022), compared with a mean of $1.7 million.
  • Biggest five-year swings in Other Accumulated Expenses: crashed 99.2% in 2022 and later skyrocketed 2301.39% in 2024.
  • Biodesix's Other Accumulated Expenses stood at $2.3 million in 2022, then rose by 24.06% to $2.9 million in 2023, then decreased by 17.31% to $2.4 million in 2024, then tumbled by 58.23% to $992000.0 in 2025, then dropped by 6.55% to $927000.0 in 2026.
  • The last three reported values for Other Accumulated Expenses were $927000.0 (Q1 2026), $992000.0 (Q4 2025), and $2.0 million (Q3 2025) per Business Quant data.